Search
for
Sort by
Research 30 of 38
- Effect of adenosine triphosphate on ribociclib-induced skin toxicity in rats
- Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Safety assessment of cyclin-dependent kinase 4/6 inhibitors and comparison of time to adverse events
- Alopecia induced by CDK 4/6 Inhibitors and its Impact on the Quality of Life of Patients with advanced Breast cancer
- Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report
- Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
- Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
- Cancer Treatments and Alopecia: A Systematic Review
- Real-World Safety Profile of Generic Palbociclib in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Prospective Observational Study in Iraq”
- Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!
- The pharmacovigilance analysis of adverse events of erlotinib based on the open access FAERS database
- Real-world pharmacovigilance insights into drug-induced risk of alopecia
- Kalya Research: Complementary and Alternative Medicine (CAM) Virtual Research Assistant from Biomedical Literature
- Hair Changes due to Drugs
- Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
- Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
- Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.
- Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
- PROTACs: A novel strategy for cancer drug discovery and development
- Poster Presentations
- Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
- Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients
- A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review
- Cancer-Related Alopecia: From Etiologies to Global Management
- Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
- Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study